A pheochromocytoma is a rare, typically non-cancerous tumour that originates in the chromaffin cells of the adrenal medulla. While these tumours can develop in individuals without any known predisposing factors, identifying high risk groups is a cornerstone of modern endocrine practice. In the United Kingdom, the incidence of these tumours is roughly 1 in every 2,500 to 5,000 people, making it a rare condition that requires specialized clinical attention. Risk is not distributed evenly across the population; instead, it is concentrated among individuals with specific genetic profiles, family histories, or existing medical syndromes. Determining who is most at risk allows the National Health Service to implement targeted screening programmes, ensuring that tumours are caught before they cause life-threatening cardiovascular events such as strokes or heart attacks.
What We’ll Discuss in This Article
- The primary age groups and demographics most commonly affected.
- The significant role of inherited genetic mutations in determining risk.
- Specific hereditary syndromes like Multiple Endocrine Neoplasia type 2.
- The link between Von Hippel Lindau disease and adrenal tumour development.
- How a family history of paragangliomas influences an individual’s risk profile.
- The impact of Neurofibromatosis type 1 on adrenal health.
- Clinical indicators that prompt doctors to screen for these rare tumours.
Age and demographic risk factors
While pheochromocytomas can occur at any age, they are most frequently diagnosed in adults between the ages of 30 and 50. Statistics from UK clinical registries indicate that there is no significant difference in risk between men and women, as the condition affects both sexes almost equally. In children, the occurrence of these tumours is exceedingly rare and is almost always associated with an underlying genetic mutation. When a pheochromocytoma is diagnosed in a younger person, it is often a major clinical red flag that prompts an immediate referral for genetic counselling. For older adults, the condition is more likely to be sporadic, meaning it occurs without a clear hereditary link. Regardless of age, the presentation of symptoms such as resistant hypertension or unexplained “panic” episodes often leads clinicians to investigate the adrenal glands as a potential source of the problem.
Multiple Endocrine Neoplasia type 2 (MEN2)
Individuals diagnosed with Multiple Endocrine Neoplasia type 2 are among those at the highest risk for pheochromocytoma. This syndrome, caused by a mutation in the RET gene, leads to a lifetime risk of approximately 50 percent for developing an adrenal tumour. Within this group, the tumours are often bilateral, meaning they occur in both adrenal glands. Patients with MEN2 are also at risk for medullary thyroid cancer, and often the thyroid issues are detected before the adrenal tumour. UK clinical guidelines from the National Institute for Health and Care Excellence emphasize that any patient with a personal or family history of medullary thyroid cancer must be screened for pheochromocytoma before undergoing any surgery to prevent a hypertensive crisis during the operation.
Von Hippel Lindau (VHL) disease carriers
Von Hippel Lindau disease is a complex genetic condition that predisposes individuals to tumours in multiple organs, including the brain, spinal cord, and kidneys. People with VHL disease have a significantly elevated risk of pheochromocytoma, with a prevalence of 10 to 20 percent depending on the specific type of VHL mutation they carry. These tumours often appear earlier in life than sporadic cases, sometimes even in childhood or adolescence. A key feature of VHL-related pheochromocytomas is that they often produce noradrenaline exclusively, which can lead to a specific pattern of symptoms. In the UK, VHL patients are managed in specialist centres where they receive regular MRI scans and biochemical tests to monitor the adrenal glands alongside other vulnerable organs.
Families with Paraganglioma-Pheochromocytoma syndromes
Those with a family history of paragangliomas are at an increased risk of developing pheochromocytomas. These syndromes are caused by mutations in the succinate dehydrogenase (SDH) genes, specifically SDHB, SDHD, and SDHC. If a person has a relative who has had a “glomus tumour” in the neck or a tumour in the abdomen, their own risk of an adrenal tumour is significantly higher. The SDHB mutation is particularly concerning for UK clinicians because it carries a higher risk of the tumour becoming malignant and spreading to other parts of the body. Because of the complexity of these mutations, including unique inheritance patterns where the disease might only manifest if inherited from the father, specialist genetic assessment is essential for these high-risk families.
Neurofibromatosis type 1 (NF1) patients
Neurofibromatosis type 1 is a relatively common genetic disorder characterized by skin changes and nerve tumours. While the majority of people with NF1 will never develop an adrenal tumour, their risk is still significantly higher than that of the general population. It is estimated that about 1 percent of people with NF1 will develop a pheochromocytoma. While this seems like a small percentage, it is high enough that UK doctors are advised to maintain a high index of suspicion if an NF1 patient develops symptoms like headaches, sweating, or high blood pressure. These tumours in NF1 patients are typically solitary and occur later in adulthood, but they still require the same careful surgical management as other forms of the condition.
Clinical indicators for screening
Beyond genetic syndromes, certain clinical findings put an individual at a higher “suspected risk” and prompt doctors to screen for the condition. This includes people with hypertension that does not respond to standard medications or those who have had an “incidentaloma” a mass on the adrenal gland found by chance during an imaging scan for an unrelated problem. Approximately 5 percent of adrenal incidentalomas turn out to be subclinical pheochromocytomas. Furthermore, people who experience sudden, dramatic spikes in blood pressure when starting certain medications or during anaesthesia are considered at high risk and require immediate biochemical testing. For clinical practitioners, the NICE guidance on managing endocrine conditions provides a framework for identifying these individuals early in the primary care setting.
Conclusion
The people most at risk for developing a pheochromocytoma are those with a known genetic syndrome such as MEN2, VHL, or NF1, as well as those with a strong family history of adrenal or nerve tumours. Age also plays a role, with most cases appearing between 30 and 50, though genetic cases can appear much earlier. In the UK, identifying these high-risk individuals is vital for the prevention of severe cardiovascular complications. If you have been diagnosed with an associated syndrome or have a family history of these tumours, regular medical surveillance is essential for your long-term health. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
Can you have a pheochromocytoma without any family history?
Yes, approximately 60 percent of cases are sporadic, meaning they occur without an identifiable genetic link or family history.
Is the risk higher for people with existing high blood pressure?
While high blood pressure is a symptom, having ordinary essential hypertension does not necessarily increase your risk of developing the tumour itself.
How early can these tumours be detected in high-risk children?
In known genetic carriers, screening often begins in early childhood, sometimes as young as five to ten years old, depending on the specific gene involved.
Does a history of other cancers increase my risk?
Only if those cancers are part of a specific syndrome like MEN2 or VHL; most common cancers do not increase the risk of a pheochromocytoma.
Are there any lifestyle factors that increase the risk?
There are no known lifestyle factors, such as diet or smoking, that cause these tumours to form; the primary drivers are genetic and biological.
What happens if I am found to be at high risk?
You will typically be referred to an endocrinologist for annual blood or urine tests and periodic imaging to monitor your adrenal glands.
Can a pheochromocytoma affect both adrenal glands?
Yes, this is much more common in people with hereditary syndromes like MEN2 or VHL than in sporadic cases.
Authority Snapshot
This article identifies the key populations at risk for pheochromocytoma to support early detection and patient education. It has been written by Dr. Rebecca Fernandez and adheres strictly to the clinical guidelines provided by the NHS and the National Institute for Health and Care Excellence. The content focuses on the high heritability of these tumours and the importance of clinical screening for individuals with known genetic predispositions within the United Kingdom.
